Acceptability of Various Available Midazolam Formulations (Syrup, Rectal Suppository, Oro-dispersible Minitablet) in Clinical Practice

RecruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions
Medication Palatability
Interventions
OTHER

Data collection on acceptability of midazolam administration by 2- to 10-year-old pediatric patients at UKBB

On the day of entry to the Anesthesiology Unit for an elective surgery, or before an intervention at the Emergency Unit, all children, irrespective of their participation to the present study, will receive standard midazolam dose of 0.3-0.5 mg/kg as prescribed by the treating clinician at UKBB in line with clinical practice (as oral syrup, rectal suppository or ODMT). The children's spontaneous reactions after intake of midazolam (e.g., positive comments, spitting out of medication, crying) will be observed and recorded by the research staff. Children who are able to understand the Hedonic Scale (FHS) will be questioned on how they liked the medication by pointing to the appropriate face of a Facial Hedonic Scale (FHS) at the time of midazolam intake.

Trial Locations (1)

4056

RECRUITING

University of Basel Children's Hospital (UKBB), Basel

All Listed Sponsors
lead

University Children's Hospital Basel

OTHER